Literature DB >> 17999053

Cardiomyocyte Ca2+ overload in atrial tachycardia: is blockade of L-type Ca2+ channels a promising approach to prevent electrical remodeling and arrhythmogenesis?

Dobromir Dobrev1.   

Abstract

Electrical remodeling paradigm has important implications for the understanding of atrial fibrillation (AF) and improvement of current treatment. Cardiomyocyte Ca(2+) overload is generally accepted as the initiating signal for the tachycardia-induced changes in atrial electrical properties (electrical remodeling). The precise role of cardiomyocyte Ca(2+) overload in AF-related ion channel alterations that contribute to AF maintenance is not fully understood. Clinically, patients with AF are often treated with Ca(2+) channel blockers such as verapamil to control their ventricular rate and to improve the success rate of cardioversion procedures. However, verapamil may produce an increased L-type Ca(2+) channel current (I(Ca,L)) that may reinforce Ca(2+) overload thereby promoting AF in the atrium. Ca(2+) channel blockers which target T-type Ca(2+) channels in addition to I(Ca,L) (for instance, efonidipine) may be more efficient at preventing Ca(2+) overload and arrhythmogenic electrical remodeling, but the potential benefits of these drugs have usually been tested in experimental models where drug administration preceded the initiation of electrical remodeling. Studies in animal models with established atrial tachycardia remodeling and in patients with AF are clearly warranted to prove the efficacy of Ca(2+) channel blockers that additionally target T-type Ca(2+) channels.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17999053     DOI: 10.1007/s00210-007-0199-x

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  17 in total

1.  A comparison between calcium channel blocking drugs with different potencies for T- and L-type channels in preventing atrial electrical remodeling.

Authors:  Narutaka Ohashi; Hideo Mitamura; Kojiro Tanimoto; Yukiko Fukuda; Osamu Kinebuchi; Yasuo Kurita; Akiko Shiroshita-Takeshita; Shunichiro Miyoshi; Motoki Hara; Seiji Takatsuki; Satoshi Ogawa
Journal:  J Cardiovasc Pharmacol       Date:  2004-09       Impact factor: 3.105

2.  Effect of verapamil on tachycardia-induced early cellular electrical remodeling in rabbit atrium.

Authors:  Roman Laszlo; Christoph Winkler; Stefan Wöhrl; Ralf E Wessel; Sara Laszlo; Mathias C Busch; Jürgen Schreieck; Ralph F Bosch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-15       Impact factor: 3.000

3.  Differential blocking action of dihydropyridine Ca2+ antagonists on a T-type Ca2+ channel (alpha1G) expressed in Xenopus oocytes.

Authors:  Taiji Furukawa; Toshihide Nukada; Reiko Miura; Kyoji Ooga; Mituyoshi Honda; Suguru Watanabe; Satoshi Koganesawa; Takaaki Isshiki
Journal:  J Cardiovasc Pharmacol       Date:  2005-03       Impact factor: 3.105

4.  Intracellular calcium changes and tachycardia-induced contractile dysfunction in canine atrial myocytes.

Authors:  H Sun; D Chartier; N Leblanc; S Nattel
Journal:  Cardiovasc Res       Date:  2001-03       Impact factor: 10.787

5.  Effect of verapamil enantiomers and metabolites on cardiac K+ channels expressed in Xenopus oocytes.

Authors:  S Waldegger; G Niemeyer; K Mörike; C A Wagner; H Suessbrich; A E Busch; F Lang; M Eichelbaum
Journal:  Cell Physiol Biochem       Date:  1999

6.  Regulation of the transient outward K(+) current by Ca(2+)/calmodulin-dependent protein kinases II in human atrial myocytes.

Authors:  S Tessier; P Karczewski; E G Krause; Y Pansard; C Acar; M Lang-Lazdunski; J J Mercadier; S N Hatem
Journal:  Circ Res       Date:  1999-10-29       Impact factor: 17.367

7.  The effects of verapamil and diltiazem on N-, P- and Q-type calcium channels mediating dopamine release in rat striatum.

Authors:  D Dobrev; A S Milde; K Andreas; U Ravens
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

8.  Chronic verapamil treatment remodels ICa,L in mouse ventricle.

Authors:  Elizabeth Schroder; Janos Magyar; Don Burgess; Douglas Andres; Jonathan Satin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-12-08       Impact factor: 4.733

9.  The tumor suppressor eIF3e mediates calcium-dependent internalization of the L-type calcium channel CaV1.2.

Authors:  Eric M Green; Curtis F Barrett; Geert Bultynck; Steven M Shamah; Ricardo E Dolmetsch
Journal:  Neuron       Date:  2007-08-16       Impact factor: 17.173

10.  Pharmacological evidence for altered src kinase regulation of I (Ca,L) in patients with chronic atrial fibrillation.

Authors:  Maura Greiser; Christian R Halaszovich; Dirk Frechen; Peter Boknik; Ursula Ravens; Dobromir Dobrev; Andreas Lückhoff; Ulrich Schotten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-06-26       Impact factor: 3.195

View more
  5 in total

Review 1.  Atrial fibrillation therapy now and in the future: drugs, biologicals, and ablation.

Authors:  Christopher E Woods; Jeffrey Olgin
Journal:  Circ Res       Date:  2014-04-25       Impact factor: 17.367

Review 2.  Ranolazine: a new approach to treating an old problem.

Authors:  Bharath M Reddy; Howard S Weintraub; Arthur Z Schwartzbard
Journal:  Tex Heart Inst J       Date:  2010

Review 3.  Novel molecular targets for atrial fibrillation therapy.

Authors:  Dobromir Dobrev; Leif Carlsson; Stanley Nattel
Journal:  Nat Rev Drug Discov       Date:  2012-03-30       Impact factor: 84.694

Review 4.  Atrial Ca2+ signaling in atrial fibrillation as an antiarrhythmic drug target.

Authors:  Dobromir Dobrev
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-09-26       Impact factor: 3.000

Review 5.  Anti-arrhythmic strategies for atrial fibrillation: The role of computational modeling in discovery, development, and optimization.

Authors:  Eleonora Grandi; Mary M Maleckar
Journal:  Pharmacol Ther       Date:  2016-09-06       Impact factor: 12.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.